In 2006, almost 500 products were launched every day across all other sectors - that's a 50% increase from 2005 and almost 100% from 2004. Yet, in that same period, the combined might of the pharmaceutical industry, the greatest R&D force in the world, both by numbers and dollars spent, launched just 21 active substances. Nostrapharmus notes that what makes this picture even bleaker is the fact that R&D spend has increased annually.
nostrapharmus www.pharma-mag.com dRug pipeLine sustainaBiLity what does the drug development industry have in common with every other major industry sector? when it comes to product development, on the surface, very little! nostrapharmus explores this in more detail. n 2006, almost 500 products were The Future is Here participants. Companies have ideas about where launched every day across all other The danger is that companies will fail to new discovery will come from; they need to be sectors — that’s a 50% increase from take advantage of this new wave, while their open to new ideas and, potentially, very disruptive 2005 and almost 100% from 2004. competitors sail out to lands anew. So, how should technologies. The challenge is balancing the Yet, in that same period, the combined might companies identify the best routes? Where should regulatory models against a fluid involvement of of the pharmaceutical industry, the greatest they invest and how should they combine the work ideas and the need for companies to move quickly R&D force in the world, both by numbers in all these fields to ensure that they are part of the and exploit new opportunities. and dollars spent, launched just 21 active next wave? No company can hope to be at the Nostrapharmus sees a hazy future for which substances. Nostrapharmus notes that what leading edge of all new technologies, nor can they companies need to be prepared. “Companies makes this picture even bleaker is the fact that expect to successfully integrate such knowledge will need to have a structure that provides a core R&D spend has increased annually. The industry easily into their existing structure. In fact, history has and stable platform around which new ideas can spent 100% more in 2006 than in 2000, yet shown that mergers and acquisitions have a mixed be assimilated, understood and, when relevant, launched half the active ingredients. So is the success rate and rarely achieve any step change pursued further or discarded. The cost of travelling industry failing to innovate? Are there structural in a company’s innovation capability. Knowing that the wrong route is astronomically greater than impediments that are driving down the rate
Pages to are hidden for
"DRUG PIPELINE SUSTAINABILITY"Please download to view full document